Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samorita HospitalDHA:SAMORITA +3.55%18 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates DHA:SAMORITA with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 478 Healthcare Providers & Services companies, Samorita Hospital ranks worse than 209204.81% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Samorita Hospital's Debt-to-EBITDA or its related term are showing as below:
DHA:SAMORITA's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.25 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Samorita Hospital Debt-to-EBITDA Related Terms
Samorita Hospital Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Samorita Hospital's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samorita Hospital Debt-to-EBITDA Chart
Samorita Hospital Annual Data
Trend
Debt-to-EBITDA
Samorita Hospital Semi-Annual Data
Debt-to-EBITDA
DHA:SAMORITA vs SPIN, USNU, CHCR: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Samorita Hospital's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samorita Hospital Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Samorita Hospital's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Samorita Hospital's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (. 20) EBITDA data.
Samorita Hospital (DHA:SAMORITA) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Samorita Hospital. According to the industry distribution chart, Samorita Hospital ranks #999999 out of 478 companies in the Healthcare Providers & Services industry.
Is Samorita Hospital's Debt-to-EBITDA too high?
Samorita Hospital's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Samorita Hospital ranks #999999 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Samorita Hospital has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Samorita Hospital's Debt-to-EBITDA compare to SPIN and USNU?
According to the Healthcare Providers & Services industry distribution chart, Samorita Hospital ranks #999999 out of 478 companies for Debt-to-EBITDA. This places Samorita Hospital in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Samorita Hospital. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samorita Hospital's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samorita Hospital stock overvalued right now?
Samorita Hospital (DHA:SAMORITA) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Samorita Hospital's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Samorita Hospital (DHA:SAMORITA), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Samorita Hospital Ltd provides general hospital services including all types of medical treatment along with diagnostic services in Bangladesh. It offers various clinical services in the areas of internal medicine, neurology, diabetes and endocrinology, nephrology, respiratory medicine, gastroenterology and other.
18GF Score
Get the complete analysis for DHA:SAMORITA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:SAMORITA has been successfully added to your 
